"Less Heart Failure Hospitalization on Dapagliflozin in Diabetes at Any LVEF, Declares DECLARE-TIMI 58"
Patients with type 2 diabetes who received dapagliflozin in the DECLARE-TIMI 58 trial showed a reduced risk for heart-failure hospitalization, regardless of their baseline left-ventricular ejection fraction. The DECLARE-TIMI 58 secondary analysis was presented during a breaking clinical trial session at the recent American College of Cardiology 68th Annual Scientific Session. “The objective of the study was not really heart failure, and I found that the number of patients with reduced ejection fraction was rather small,” said Valentin Fuster, MD, PhD, director of Mount Sinai Heart. “I would call these preliminary data.”
— Valentin Fuster, MD, PhD, Director, Mount Sinai Heart, Physician in Chief, The Mount Sinai Hospital, Professor, Medicine, Cardiology, Icahn School of Medicine at Mount Sinai
Heart Injury Among Hospitalized COVID-19 Patients Associated with Higher Risk of DeathJun 08, 2020 View All Press Releases